Consequently, although PD-L1 continues to represent a promising target for therapeutic intervention, the variability of its expression in DLBCL underscores the necessity for personalized treatment strategies that specifically concentrate on this pathway. The gene discussed is CD274; the disease is diffuse large B-cell lymphoma.